Expert Ratings for Bio-Techne
Portfolio Pulse from Benzinga Insights
Bio-Techne (NASDAQ:TECH) has received mixed analyst ratings in the last quarter, with 3 bullish, 1 somewhat bullish, and 2 indifferent. The average 12-month price target among 6 analysts is $79.0, with a high of $86.00 and a low of $65.00. This target is a 21.78% decrease from the previous target of $101.00. Analysts' ratings are based on company data, financial statements, and insider information.
December 07, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Techne has a mix of bullish and indifferent analyst ratings with a decreased average price target of $79, suggesting a cautious outlook from analysts.
The mixed analyst ratings and the significant decrease in the average price target could lead to uncertainty among investors, potentially causing short-term price stability rather than a clear direction. The ratings are a mix of bullish and indifferent, which does not strongly suggest a move in either direction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100